Scleroderma Clinical Trials Consortium is ranked #1 of 12 medical research organizations in Boston, MA, with an America's Best Score of 100 out of 100, based on its 2024 Form 990. It's named America's Best 2026.
Scleroderma Clinical Trials Consortium is a 501(c)(3) organization, classified under Medical Research (NTEE H99). Contributions are tax-deductible.
Bu Sch Medicine 718 Albany St E-5, Boston, MA 02118-0000
Among the 13 scored medical research organizations in Boston, Scleroderma Clinical Trials Consortium holds 160 months of operating reserves (peer median 14.1 months), runs a typical yearly surplus of 25.8% (peers: surplus of 25.8%), and has grown spending 29.7% a year (peers: grown spending 11.8% a year).
In fiscal year 2024 it reported $326,433 in revenue and $298,602 in expenses, with contributions making up 66.5% of revenue.
To foster scientific research and to advance medical research in the form of treatment trials in scleroderma on a worldwide basis.
Main program · fiscal year 2024
To foster scientific research and to advance medical research in the form of treatment trials in scleroderma on a worldwide basis.$286,656 spent
Where each dollar went · fiscal year 2024
Of every dollar it spent, 96¢ went to programs, 4¢ to management and 0¢ to fundraising.
Programs $286,656
Management $11,946
Fundraising $0
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Peers: the 13 Boston medical research organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$326,433Fiscal year 2024
Expenses$298,602Fiscal year 2024
Total assets$4,030,611Fiscal year 2024
Total liabilities$50,000Fiscal year 2024
Fiscal year ending December2024
Revenue$326,433
Expenses$298,602
Net income$27,831
Net assets$3,980,611
Notable sources of revenue
Percent of total revenue
Contributions
$217,229
66.5%
Program services
$0
0.0%
Investment income
$109,204
33.5%
Other (net)
$0
0.0%
Assets / debt
Total assets
$4,030,611
Total liabilities
$50,000
Net assets
$3,980,611
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$264,484
Expenses$210,242
Net income$54,242
Net assets$2,590,652
Notable sources of revenue
Percent of total revenue
Contributions
$188,821
71.4%
Program services
$0
0.0%
Investment income
$75,663
28.6%
Other (net)
$0
0.0%
Assets / debt
Total assets
$3,466,894
Total liabilities
$876,242
Net assets
$2,590,652
Compensation
Officers and key employees
$0
Share of expenses
0.0%
Fiscal year ending December2022
Revenue$271,981
Expenses$177,441
Net income$94,540
Net assets$2,536,410
Notable sources of revenue
Percent of total revenue
Contributions
$188,315
69.2%
Program services
$0
0.0%
Investment income
$83,666
30.8%
Other (net)
$0
0.0%
Assets / debt
Total assets
$2,536,410
Total liabilities
$0
Net assets
$2,536,410
Compensation
Officers and key employees
$0
Share of expenses
0.0%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?